![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EGFR |
Gene summary for EGFR |
![]() |
Gene information | Species | Human | Gene symbol | EGFR | Gene ID | 1956 |
Gene name | epidermal growth factor receptor | |
Gene Alias | ERBB | |
Cytomap | 7p11.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q504U8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1956 | EGFR | CA_HPV_1 | Human | Cervix | CC | 2.14e-07 | -2.95e-01 | 0.0264 |
1956 | EGFR | CA_HPV_3 | Human | Cervix | CC | 1.15e-12 | 3.49e-01 | 0.0414 |
1956 | EGFR | CCI_1 | Human | Cervix | CC | 1.13e-21 | 2.02e+00 | 0.528 |
1956 | EGFR | CCI_2 | Human | Cervix | CC | 4.65e-04 | 1.18e+00 | 0.5249 |
1956 | EGFR | CCI_3 | Human | Cervix | CC | 8.86e-25 | 1.67e+00 | 0.516 |
1956 | EGFR | Tumor | Human | Cervix | CC | 1.95e-06 | 3.01e-01 | 0.1241 |
1956 | EGFR | sample3 | Human | Cervix | CC | 1.78e-19 | 4.03e-01 | 0.1387 |
1956 | EGFR | T3 | Human | Cervix | CC | 1.92e-12 | 3.21e-01 | 0.1389 |
1956 | EGFR | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.41e-08 | -4.24e-01 | 0.0155 |
1956 | EGFR | HTA11_347_2000001011 | Human | Colorectum | AD | 3.34e-10 | 6.12e-01 | -0.1954 |
1956 | EGFR | HTA11_411_2000001011 | Human | Colorectum | SER | 5.78e-04 | 7.22e-01 | -0.2602 |
1956 | EGFR | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.02e-13 | -4.52e-01 | 0.294 |
1956 | EGFR | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.95e-07 | -4.41e-01 | 0.3859 |
1956 | EGFR | HTA11_99999974143_84620 | Human | Colorectum | MSS | 5.21e-27 | -6.79e-01 | 0.3005 |
1956 | EGFR | F007 | Human | Colorectum | FAP | 3.80e-04 | -3.45e-01 | 0.1176 |
1956 | EGFR | A015-C-203 | Human | Colorectum | FAP | 7.86e-35 | -4.60e-01 | -0.1294 |
1956 | EGFR | A015-C-204 | Human | Colorectum | FAP | 1.06e-05 | -3.33e-01 | -0.0228 |
1956 | EGFR | A014-C-040 | Human | Colorectum | FAP | 1.30e-03 | -3.14e-01 | -0.1184 |
1956 | EGFR | A002-C-201 | Human | Colorectum | FAP | 1.67e-18 | -5.41e-01 | 0.0324 |
1956 | EGFR | A001-C-119 | Human | Colorectum | FAP | 1.90e-10 | -6.44e-01 | -0.1557 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00094109 | Cervix | CC | response to xenobiotic stimulus | 78/2311 | 462/18723 | 2.39e-03 | 1.70e-02 | 78 |
GO:00507148 | Cervix | CC | positive regulation of protein secretion | 29/2311 | 137/18723 | 2.40e-03 | 1.70e-02 | 29 |
GO:00974217 | Cervix | CC | liver regeneration | 11/2311 | 35/18723 | 2.43e-03 | 1.71e-02 | 11 |
GO:00457404 | Cervix | CC | positive regulation of DNA replication | 12/2311 | 40/18723 | 2.44e-03 | 1.71e-02 | 12 |
GO:00303235 | Cervix | CC | respiratory tube development | 36/2311 | 181/18723 | 2.46e-03 | 1.71e-02 | 36 |
GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
GO:00702542 | Cervix | CC | mucus secretion | 6/2311 | 13/18723 | 2.78e-03 | 1.87e-02 | 6 |
GO:20003779 | Cervix | CC | regulation of reactive oxygen species metabolic process | 32/2311 | 157/18723 | 2.78e-03 | 1.87e-02 | 32 |
GO:1900087 | Cervix | CC | positive regulation of G1/S transition of mitotic cell cycle | 13/2311 | 46/18723 | 2.95e-03 | 1.94e-02 | 13 |
GO:00459302 | Cervix | CC | negative regulation of mitotic cell cycle | 44/2311 | 235/18723 | 3.02e-03 | 1.99e-02 | 44 |
GO:00463285 | Cervix | CC | regulation of JNK cascade | 28/2311 | 133/18723 | 3.06e-03 | 2.01e-02 | 28 |
GO:00605413 | Cervix | CC | respiratory system development | 39/2311 | 203/18723 | 3.18e-03 | 2.07e-02 | 39 |
GO:00486593 | Cervix | CC | smooth muscle cell proliferation | 36/2311 | 184/18723 | 3.27e-03 | 2.13e-02 | 36 |
GO:19011857 | Cervix | CC | negative regulation of ERBB signaling pathway | 10/2311 | 32/18723 | 3.96e-03 | 2.48e-02 | 10 |
GO:00486603 | Cervix | CC | regulation of smooth muscle cell proliferation | 35/2311 | 180/18723 | 4.10e-03 | 2.54e-02 | 35 |
GO:00487712 | Cervix | CC | tissue remodeling | 34/2311 | 175/18723 | 4.68e-03 | 2.82e-02 | 34 |
GO:00420597 | Cervix | CC | negative regulation of epidermal growth factor receptor signaling pathway | 9/2311 | 28/18723 | 5.02e-03 | 2.98e-02 | 9 |
GO:00331353 | Cervix | CC | regulation of peptidyl-serine phosphorylation | 29/2311 | 144/18723 | 5.10e-03 | 3.01e-02 | 29 |
GO:00703723 | Cervix | CC | regulation of ERK1 and ERK2 cascade | 54/2311 | 309/18723 | 5.11e-03 | 3.02e-02 | 54 |
GO:00609647 | Cervix | CC | regulation of gene silencing by miRNA | 13/2311 | 49/18723 | 5.34e-03 | 3.10e-02 | 13 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517120 | Cervix | CC | Coronavirus disease - COVID-19 | 111/1267 | 232/8465 | 1.82e-33 | 5.90e-31 | 3.49e-31 | 111 |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0491520 | Cervix | CC | Estrogen signaling pathway | 44/1267 | 138/8465 | 3.55e-07 | 3.97e-06 | 2.35e-06 | 44 |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0401512 | Cervix | CC | Rap1 signaling pathway | 56/1267 | 210/8465 | 6.23e-06 | 5.61e-05 | 3.32e-05 | 56 |
hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
hsa051207 | Cervix | CC | Epithelial cell signaling in Helicobacter pylori infection | 24/1267 | 70/8465 | 4.35e-05 | 3.09e-04 | 1.83e-04 | 24 |
hsa0521010 | Cervix | CC | Colorectal cancer | 27/1267 | 86/8465 | 8.60e-05 | 5.57e-04 | 3.30e-04 | 27 |
hsa052197 | Cervix | CC | Bladder cancer | 16/1267 | 41/8465 | 1.45e-04 | 9.05e-04 | 5.35e-04 | 16 |
hsa052148 | Cervix | CC | Glioma | 24/1267 | 75/8465 | 1.51e-04 | 9.20e-04 | 5.44e-04 | 24 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa052128 | Cervix | CC | Pancreatic cancer | 24/1267 | 76/8465 | 1.89e-04 | 1.11e-03 | 6.55e-04 | 24 |
hsa015223 | Cervix | CC | Endocrine resistance | 28/1267 | 98/8465 | 3.82e-04 | 1.87e-03 | 1.11e-03 | 28 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0491212 | Cervix | CC | GnRH signaling pathway | 26/1267 | 93/8465 | 8.72e-04 | 3.87e-03 | 2.29e-03 | 26 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
AREG | EGFR | AREG_EGFR | EGF | Breast | ADJ |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | ADJ |
AREG | EGFR | AREG_EGFR | EGF | Breast | DCIS |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Breast | DCIS |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | DCIS |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Breast | DCIS |
EREG | EGFR | EREG_EGFR | EGF | Breast | DCIS |
EREG | EGFR_ERBB2 | EREG_EGFR_ERBB2 | EGF | Breast | DCIS |
AREG | EGFR | AREG_EGFR | EGF | Breast | Healthy |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Healthy |
EREG | EGFR | EREG_EGFR | EGF | Breast | Healthy |
AREG | EGFR | AREG_EGFR | EGF | Breast | Precancer |
HBEGF | EGFR | HBEGF_EGFR | EGF | Breast | Precancer |
EREG | EGFR | EREG_EGFR | EGF | Breast | Precancer |
AREG | EGFR | AREG_EGFR | EGF | Cervix | ADJ |
HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | ADJ |
AREG | EGFR | AREG_EGFR | EGF | Cervix | CC |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Cervix | CC |
HBEGF | EGFR | HBEGF_EGFR | EGF | Cervix | CC |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Cervix | CC |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EGFR | SNV | Missense_Mutation | novel | c.941N>G | p.Asp314Gly | p.D314G | P00533 | protein_coding | tolerated(0.26) | benign(0.031) | TCGA-A2-A4S3-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | rs532655845 | c.439G>A | p.Ala147Thr | p.A147T | P00533 | protein_coding | deleterious(0.02) | benign(0.027) | TCGA-A7-A6VX-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | CR |
EGFR | SNV | Missense_Mutation | c.3151N>A | p.Asp1051Asn | p.D1051N | P00533 | protein_coding | tolerated(0.6) | benign(0.001) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
EGFR | SNV | Missense_Mutation | c.1577G>C | p.Cys526Ser | p.C526S | P00533 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-AR-A0TV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-AR-A2LR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
EGFR | SNV | Missense_Mutation | rs201717672 | c.3602N>T | p.Ala1201Val | p.A1201V | P00533 | protein_coding | deleterious(0.01) | benign(0.284) | TCGA-B6-A0RQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | rs138847501 | c.769G>A | p.Glu257Lys | p.E257K | P00533 | protein_coding | deleterious(0.01) | benign(0.206) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EGFR | SNV | Missense_Mutation | c.2540N>A | p.Thr847Lys | p.T847K | P00533 | protein_coding | deleterious(0) | possibly_damaging(0.555) | TCGA-C8-A1HG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P00533 | protein_coding | deleterious(0.04) | benign(0.012) | TCGA-D8-A1JF-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
EGFR | SNV | Missense_Mutation | rs121913465 | c.2303N>T | p.Ser768Ile | p.S768I | P00533 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | AMG 595 | |||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 249565586 | POZIOTINIB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL1201827 | PANITUMUMAB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 385612228 | ||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | gefitinib | GEFITINIB | 18681783,17375033,22370314,14990633,16467544,16377102,17317677,14990632,18784101,17020982,19473722,21921847,16912157,19589612,20573926,16258541,19692680,22581822,17192902,16203769,16257339,17429313,18000659,17085664,18003960,19381876,17473659,15897572,22215752,26490356,23022519,21900837,20038723,16865253,11255078,17285735,15118073,20022809,16115929,19339720,18316547,19201048,22760226,16204011,16956694,17597605,12648464,21233402,18992959,22237259,22594511 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | Pyrrolo[2,3-d]pyrimidine derivative 24 | |||
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | INC280 | CAPMATINIB | 28783719 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 363894206 | ALLITINIB | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | CHEMBL422872 | AZD-4769 | |
1956 | EGFR | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, CELL SURFACE, TYROSINE KINASE, DRUG RESISTANCE | inhibitor | 315661259 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 |